HVAX Technologies Strengthens Business Momentum with ₹312.58 Cr Order Book and Robust Pipeline

Explores M&A Opportunities and Global Expansion Across GCC, Asia-Pacific & LATAM

Mumbai– 19th September, 2025 – HVAX Technologies Limited (NSE - HVAX), a turnkey pharmaceutical project integrator, has announced key business highlights that reinforce its strong growth trajectory.

Order Book and Pipeline

HVAX reported a **consolidated order book of ₹312.58 Cr** as of September 2025. In addition, the company is actively engaged **in negotiations for projects worth ₹681.53 Cr**.

Strategic Growth Moves

HVAX has aggressively begun penetrating the hospital industry and remains optimistic about achieving a breakthrough in the near future. The company has also started evaluating opportunities in the semiconductor and solar industries.

The company aims to evaluate and acquire businesses **by leveraging existing relationships with partners already serving the healthcare sector,** enabling efficient market penetration and stronger networks. By addressing the **growing needs of India's rapidly expanding hospital services market,** HVAX expects to accelerate its entry into these high-growth areas. This **synergistic expansion is expected to create value for shareholders and contribute meaningfully to the healthcare ecosystem.**

Expanding Global Footprint

In parallel, **HVAX is in discussions with global agencies to explore strategic tie-ups and expansion in the GCC, Asia-Pacific, and LATAM regions.** These geographies present significant opportunities, and HVAX aims to leverage its expertise in delivering **precision-driven, compliant, and innovative infrastructure solutions.**

For Further Information Please Contact Corporate Communication Advisor

Kirin Advisors	**Kirin Advisors Private Limited** Sunil Mudgal – Director sunil@kirinadvisors.com +91 98692 75849 www.kirinadvisors.com